| Autor: |
D E, Furst, H, Lindsley, B, Baethge, G R, Botstein, J, Caldwell, F, Dietz, R, Ettlinger, H E, Golden, G E, McLaughlin, L W, Moreland, W N, Roberts, T W, Rooney, B, Rothschild, M, Sack, A I, Sebba, M, Weisman, K E, Welch, D, Yocum |
| Rok vydání: |
1999 |
| Předmět: |
|
| Zdroj: |
Arthritis and rheumatism. 42(2) |
| ISSN: |
0004-3591 |
| Popis: |
To investigate the usefulness of hydroxychloroquine (HCQ) dose-loading to increase the percentage of responders or rate of response in treating rheumatoid arthritis (RA).Two hundred twelve patients with early RA (mean duration 1.5 years) were enrolled in a 24-week trial. Patients were stabilized with 1,000 mg naproxen/day and then began a 6-week, double-blind trial comparing treatment with HCQ at 400 mg/day (n = 71), 800 mg/day (n = 71), and 1,200 mg/day (n = 66), followed by 18 weeks of open-label HCQ treatment at 400 mg/day.All patients had mild, active disease at the time of initiation of HCQ treatment (31-43% rheumatoid factor positive; no previous disease-modifying antirheumatic drugs; mean swollen joint count 8.6-10.4). Based on the Paulus criteria, response during the 6-week double-blind portion of the study was 47.97%, 57.7%, and 63.6% in the 400 mg/day, 800 mg/day, and 1,200 mg/day groups, respectively (P = 0.052). Discontinuations for adverse events were dose related (3 in the 400 mg/day group, 5 in the 800 mg/day group, 6 in the 1,200 mg/day group). Most involved the gastrointestinal (GI) system, with the background naproxen treatment possibly contributing. Ocular abnormalities occurred in 17 of 212 patients (8%) but were not dose related.Dose-loading with HCQ increased the degree of response at 6 weeks in this group of patients with early, predominantly seronegative RA. Adverse GI events were dose related, while adverse ocular events were not. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text